Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04532281RecruitingEarly Phase 1
CD19 CAR-T therapy for relapsed or resistant blood cancers
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Hangzhou, ZhejiangAges Any age - NCT04532203RecruitingEarly Phase 1
CAR-T therapy for leukemia or lymphoma in the brain
This early-phase study tests CAR-T cells—immune cells engineered to recognize cancer—for people whose leukemia or lymphoma has spread to the central nervous system (the brain/spinal fluid). It may help shrink or control hard-to-treat (relapsed or refractory) cancers in the brain.
Hangzhou, ZhejiangAges 3–75 - NCT04665674Recruiting
Study of adults with pulmonary Langerhans cell histiocytosis
This study follows adults with a specific lung condition to better understand how it behaves over time. If you have the right diagnosis, joining could help researchers learn what to expect and how to manage it.
ParisAges 18 years+ - NCT04824950Recruiting
Blood DNA test in newly diagnosed mediastinal large B-cell lymphoma
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
LyonAges 18 years+ - NCT04829708RecruitingPhase 3
Preventing brain spread in limited-stage small cell lung cancer
This trial compares two ways to manage limited-stage small cell lung cancer that has improved after initial chemotherapy and radiation. Participants will either get preventive brain radiation or have regular brain MRI scans instead, to see which approach is safer and works better.
Jinan, ShandongAges 18–75 - NCT03791034Recruiting
Blood DNA test to guide treatment in early lung cancer
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
SeoulAges 18–90 - NCT03869619Recruiting
Real-life data study for adults with recent lymphoma
This study collects “real-world” health information about adults whose lymphoma was diagnosed within the last 6 months. It aims to better understand lymphoma types and how patients do over time, using data from everyday care rather than testing a new drug.
ArrasAges 18 years+ - NCT05033691Recruiting
Osimertinib plus early brain radiation versus osimertinib alone
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
JerusalemAges 18–120 - NCT04670029RecruitingPhase 3
Testing an APA program to improve outcomes in large B-cell lymphoma
This Phase 3 trial studies whether an APA program (an added supportive program during care) can improve event-free survival for people with diffuse large B-cell lymphoma. It may help by supporting patients during standard first-line treatment so they do better over time.
BesançonAges 65 years+ - NCT04519905Recruiting
Testing two ways of radiation in older esophagus cancer patients
This study compares a planned radiation approach given at the same time as other treatment for older adults with esophageal squamous cell carcinoma. It may help find a safer and more effective radiation schedule for people who are fit enough for treatment.
Nanjing, JiangsuAges 76 years+ - NCT05104788RecruitingPhase 2
Icotinib plus chemotherapy before surgery for EGFR lung cancer
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
BeijingAges 18–75 - NCT05124951RecruitingPhase 2
Tested a treatment for specific brain germ cell tumors
This Phase 2 trial studies WVI for children and young adults with a newly diagnosed germ cell tumor in one side of the basal ganglia/thalamus. It aims to see how well the treatment works for tumors without spread within the brain.
BeijingAges 3–30 - NCT05240950RecruitingPhase 1
CAR-T cell therapy for colorectal cancer in the liver
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05326295Recruiting
Breast cancer study using tumor cells in blood
This trial checks whether a blood test that looks at tumor cells can help guide treatment for people with breast cancer. If you join, your care team will follow your responses over time to see if this “phenotype surveillance” approach is useful.
Changsha, HunanAges 18–75 - NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT05037825Recruiting
Study gut microbes with immune therapy in several solid cancers
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Elizabethtown, KentuckyAges 18 years+ - NCT04657861RecruitingEarly Phase 1
BCMA/TACI CAR-T for relapsed or refractory multiple myeloma
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT04951635RecruitingPhase 3
Almonertinib after chemoradiation for stage III lung cancer
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Ji'nan, ShandongAges 18 years+ - NCT04973306RecruitingPhase 2/Phase 3
Chemo-immunotherapy before surgery versus chemo-radiation
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
ShanghaiAges 18–75 - NCT05455918RecruitingPhase 2
Chemo with paclitaxel, ifosfamide, and cisplatin for high-risk germ cell tumors
This Phase 2 trial tests a specific chemotherapy combination (paclitaxel, ifosfamide, and cisplatin) for children and teens with newly diagnosed, high-risk germ cell tumors. It aims to improve outcomes by treating cancer cells with a stronger chemo plan.
SeoulAges 1–20 - NCT05025813RecruitingPhase 2
Pembrolizumab before surgery or radiation for high-risk skin SCC
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
Camperdown, New South WalesAges 18 years+ - NCT05506410Recruiting
Newly diagnosed mantle cell lymphoma study with Hanlikang and BTK drugs
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
Zhengzhou, HenanAges 18–90 - NCT03240328RecruitingPhase 1
CAR-T therapy study for rebuilding HIV immune defenses
This early-stage study tests whether CAR-T cells can help rebuild the immune system’s ability to fight HIV. You may be a candidate if your HIV is well controlled on standard treatment and you don’t have certain serious infections or organ problems.
Guangzhou, GuangdongAges 18–60 - NCT05611515Recruiting
New treatment plan for early supraglottic throat cancer
This trial tests a treatment approach for early-stage supraglottic (upper voice box) squamous cell carcinoma. It may help improve outcomes while also tracking quality of life during and after treatment.
Yvoir, NamurAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.